Literature DB >> 17937066

Development of pulmonary hypertension in an infant treated with diazoxide.

Todd D Nebesio1, Wynton C Hoover, Randall L Caldwell, Mara E Nitu, Erica A Eugster.   

Abstract

Diazoxide is commonly used in the treatment of neonatal hyperinsulinism. We describe a one month-old infant who was treated with diazoxide for prolonged neonatal hyperinsulinism. Shortly after starting diazoxide, she was admitted to the hospital for tachypnea with hypoxemia, and was subsequently diagnosed with laryngomalacia and obstructive apnea. During hospitalization, her clinical course worsened due to the development of severe pulmonary hypertension, presumed due to diazoxide toxicity. Lung biopsy revealed a probable toxic vascular drug reaction. After discontinuing diazoxide, her clinical status improved and eventually returned to baseline.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17937066     DOI: 10.1515/jpem.2007.20.8.939

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  13 in total

1.  Liver injury may increase the risk of diazoxide toxicity: a case report.

Authors:  Emir Tas; Burhanuddin Mahmood; Luigi Garibaldi; Mark Sperling
Journal:  Eur J Pediatr       Date:  2015-01-25       Impact factor: 3.183

Review 2.  The management of hypertensive emergencies in children after stem cell transplantation.

Authors:  D G Horn; M N Trame; G Hempel
Journal:  Int J Clin Pharm       Date:  2011-03-12

Review 3.  Development of Pulmonary Hypertension During Treatment with Diazoxide: A Case Series and Literature Review.

Authors:  Matthew R Timlin; Alexander B Black; Heather M Delaney; Renée I Matos; Candace S Percival
Journal:  Pediatr Cardiol       Date:  2017-06-22       Impact factor: 1.655

4.  Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability.

Authors:  Bashkim Kadriu; Shiwen Yuan; Cristan Farmer; Allison C Nugent; Marc S Lener; Mark J Niciu; Minkyung Park; Aaron Yazdian; Elizabeth D Ballard; Fritz A Henn; Ioline D Henter; Lawrence T Park; Carlos A Zarate
Journal:  J Clin Psychopharmacol       Date:  2018-06       Impact factor: 3.153

5.  Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.

Authors:  Adriana Herrera; Mary Ellen Vajravelu; Stephanie Givler; Lauren Mitteer; Catherine M Avitabile; Katherine Lord; Diva D De León
Journal:  J Clin Endocrinol Metab       Date:  2018-12-01       Impact factor: 5.958

Review 6.  Update on neonatal hypoglycemia.

Authors:  Paul J Rozance
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-02       Impact factor: 3.243

Review 7.  Congenital Hyperinsulinism: Diagnosis and Treatment Update.

Authors:  Hüseyin Demirbilek; Khalid Hussain
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-12-27

Review 8.  Pulmonary hypertension's variegated landscape: a snapshot.

Authors:  Thomas J Kulik; Eric D Austin
Journal:  Pulm Circ       Date:  2017-03-13       Impact factor: 3.017

9.  Prevalence and safety of diazoxide in the neonatal intensive care unit.

Authors:  Keyaria D Gray; Kathryn Dudash; Carla Escobar; Colman Freel; Tylah Harrison; Chandler McMillan; Mihai Puia-Dumitrescu; C Michael Cotten; Robert Benjamin; Reese H Clark; Daniel K Benjamin; Rachel G Greenberg
Journal:  J Perinatol       Date:  2018-09-11       Impact factor: 3.225

10.  Possible New Strategies for the Treatment of Congenital Hyperinsulinism.

Authors:  Jelena Sikimic; Theresa Hoffmeister; Anne Gresch; Julia Kaiser; Winfried Barthlen; Carmen Wolke; Ilse Wieland; Uwe Lendeckel; Peter Krippeit-Drews; Martina Düfer; Gisela Drews
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-27       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.